Capital Fund Management S.A. Clovis Oncology, Inc. Transaction History

Capital Fund Management S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$4.82 - $7.72 $748,473 - $1.2 Million	-155,285 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$5.69 - $9.69 $753,356 - $1.28 Million	132,400 Added 578.54%	155,285 $1.05 Million
Q1 2020 May 13, 2020	BUY	$3.77 - $11.0 $86,276 - $251,735	22,885 New	22,885 $145,000
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $1.04 Million - $1.76 Million	-35,524 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $1.49 Million - $2.22 Million	35,524 New	35,524 $1.62 Million
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $2.53 Million - $3.42 Million	-50,471 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$57.69 - $84.58 $2.1 Million - $3.08 Million	36,472 Added 260.53%	50,471 $3.43 Million
Q3 2017 Nov 13, 2017	BUY	$67.17 - $84.81 $940,312 - $1.19 Million	13,999	13,999 $1.15 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.